Fund II

Verifarma provides integrated software solutions for the pharmaceutical and life sciences industry, spanning serialization and traceability, quality management (eQMS), regulatory affairs, and pharmacovigilance. Its platform enables end-to-end visibility and compliance across the supply chain, helping companies meet global regulatory requirements and ensure the safety and authenticity of medicines. By integrating data, compliance workflows, and traceability systems into a unified platform, Verifarma enables more efficient, transparent, and scalable operations - aligned with MTIP’s focus on software-driven infrastructure in highly regulated healthcare markets.

Fund II

Dossier is a healthcare competency management SaaS provider. The company helps hospitals streamline regulatory compliance and enhance patient care by automating the tracking of staff competencies, reducing administrative burdens, and improving care quality and outcomes.

Fund II

Hexarad delivers a radiology platform that streamlines imaging workflows and reporting. Its software integrates across clinical systems to manage the end-to-end radiology process, including scan allocation, reporting, and data flow, helping departments handle increasing imaging demand more efficiently. By combining workflow automation with data-driven insights and AI capabilities, Hexarad helps radiology teams optimize operations, reduce diagnostic delays, and improve resource utilization - aligned with MTIP’s focus on software and AI-enabled solutions that increase efficiency in radiology departments.

Fund II

Caresyntax develops a surgical intelligence platform that integrates and analyses data from the operating room to improve clinical and operational performance. Its software connects video, device, and clinical data to deliver actionable insights across surgical workflows. By leveraging data and AI-driven insights, Caresyntax enables safer, more efficient surgeries, improves patient outcomes, and optimizes resource utilization - aligned with MTIP’s focus on scalable, data-driven healthcare solutions.

Fund II

LynxCare offers an AI-powered clinical data platform that mines structured and unstructured health data from hospital information systems with high accuracy and scalability. Its platform uses natural language processing to unlock the value of clinical data and make it accessible for hospitals and pharmaceutical companies. By transforming real-world data into validated real-world evidence, LynxCare supports clinical research and data-driven decision-making - aligned with MTIP’s focus on data-driven solutions that enhance efficiency in pharmaceutical development.

Fund II

Apricity brought digital-first fertility care, combining clinical expertise with technology-enabled treatment pathways to support patients throughout the fertility journey. As a virtual fertility clinic, its platform reduced the need for in-person visits while providing personalized care through a seamless, app-based experience. By integrating data and digital tools into care delivery, Apricity improved patient experience, increased the likelihood of successful outcomes, and expanded access to fertility treatment -aligned with MTIP’s focus on digital solutions that deliver better care to patients.

Fund II

Intelligencia AI enables AI-powered decision-making in drug development. Its platform analyzes clinical and scientific data to predict the probability of success of drug candidates, helping pharmaceutical and biotech companies prioritize assets and reduce development risk. By combining machine learning with large-scale data integration, Intelligencia AI delivers faster, more informed R&D decisions, improving capital allocation and increasing the likelihood of successful outcomes - aligned with MTIP’s focus on data-driven solutions that enhance efficiency in pharmaceutical R&D.

Fund II

Mediktor brings AI-powered symptom assessment and digital triage to healthcare, guiding patients to the appropriate level of care. Its platform analyzes patient-reported symptoms using natural language processing and clinical algorithms to provide pre-diagnostic insights and care navigation. By integrating AI-driven triage into healthcare workflows, Mediktor improves patient access, reduces unnecessary visits, and optimizes resource utilization - aligned with MTIP’s focus on scalable, data-driven solutions that enhance operational efficiency in healthcare delivery.

Fund II

Trialbee provides software and data-driven solutions that improve patient recruitment and engagement in clinical trials. Its platform connects sponsors, sites, and patients, enabling faster enrollment, better retention, and more efficient trial execution. By leveraging data and AI to optimize patient matching and outreach, Trialbee addresses a critical bottleneck in drug development - fitting MTIP’s strategy of backing technology that enhances efficiency across the healthcare value chain.

Fund I

TytoCare provides a telehealth solution that combines a handheld medical examination device with a digital platform, enabling clinicians to perform remote physical exams and diagnose patients from home. Its system captures clinical-grade data - including heart, lung, ear, throat, and skin assessments - and integrates with telehealth workflows to support accurate and timely care delivery. By combining connected medical devices with virtual care capabilities, TytoCare supports more accessible, efficient, and patient-centric healthcare delivery - aligned with MTIP’s focus on AI-enabled solutions that expand access and improve care.

Fund II

Oviva specializes in personalized coaching and tailored nutrition advice, delivered digitally, to assist with management of diabetes and obesity

Fund I

Nitinotes develops minimally invasive surgical devices for bariatric procedures, enabling physicians to perform incisionless sleeve gastroplasty using endoscopic techniques. Its technology allows for effective weight-loss treatment without the need for traditional surgery, reducing procedural risk and recovery time while improving patient outcomes. By combining medical device design with minimally invasive approaches, Nitinotes enables safer and more efficient obesity treatment.

Fund I

Quanta offers a compact, cartridge-based hemodialysis system designed for use across hospitals, clinics, and home settings. Its solution simplifies dialysis delivery by eliminating the need for complex disinfection processes, reducing treatment time, and enabling flexible use across care settings - helping improve patient outcomes and access to care. By combining medical device innovation with a user-friendly and scalable design, Quanta supports more efficient and patient-centric dialysis care across the continuum.

Fund I

Cynerio provided a cybersecurity platform purpose-built for healthcare, enabling hospitals and health systems to secure connected medical devices and clinical networks through real-time visibility, risk detection, and automated protection - aligned with MTIP’s focus on software-driven healthcare solutions. In July 2025, Cynerio was acquired by Axonius, an asset intelligence platform that integrates data across IT environments to deliver comprehensive visibility and actionable insights, enabling organizations to better manage risk, improve efficiency, and optimize resource utilization.

Fund I

Lumeon developed a care orchestration platform that automates and coordinates clinical workflows across healthcare organizations. Its software integrated with existing systems to manage end-to-end patient pathways, reducing manual tasks and ensuring consistent, data-driven care delivery. By combining workflow automation with real-time data and clinical intelligence, Lumeon helped healthcare providers streamline operations, improve care coordination, and increase efficiency - supporting MTIP’s investment strategy in scalable software solutions that modernize healthcare operations.

Fund I

Coramaze focuses on developing a minimally invasive transcatheter system for the treatment of tricuspid regurgitation, a severe heart valve condition with limited therapeutic options. Its Tripair™ technology is designed to simplify valve repair procedures, aimed at safer and more accessible treatment across a broader patient population. By combining medical device innovation with a simplified procedural approach, Coramaze supports more accessible and effective treatment of structural heart disease.

Fund I

Blueprint Genetics is a genetic testing company focused on inherited diseases. Its platform combines clinical-grade sequencing with advanced variant interpretation to enable accurate diagnosis and more informed treatment decisions. In 2020, Blueprint Genetics was acquired by Quest Diagnostics, where its capabilities continue to support the expansion of genetic testing and diagnostics services, improving access to high-quality insights in rare diseases.

Fund I

Reactive Robotics offers a mobilization robot enabling faster recovery for Intensive Care Unit “ICU” patients